Clinical Trial

A Study of MG2512 Injection in Participants With Advanced Solid Tumors

Name: A Study of MG2512 Injection in Participants With Advanced Solid Tumors — clinical trial record (NCT07348653)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is an open-label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of MG2512 injection in participants with advanced solid tumors.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-13

Trial Details

NCT Number	NCT07348653
Lead Sponsor	Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Conditions	Advanced Solid Tumor
Enrollment	116 participants
Start Date	2026-03-18
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-12